尼泊卡利单抗治疗全身型重症肌无力患者的安全性与疗效:随机2期Vivacity-MG研究结果
这项2期研究将68例全身型重症肌无力患者随机分配至安慰剂组或四种尼泊卡利单抗静脉给药方案组,评估安全性与疗效。尼泊卡利单抗总体安全、耐受性良好,第57天MG-ADL评分呈现显著剂量依赖性降低(线性趋势检验p=0.031),支持进一步评估其治疗全身型重症肌无力。
要点
- 尼泊卡利单抗组与安慰剂组治疗中出现的不良事件发生率相似(83.3% vs 78.6%)。
- 尼泊卡利单抗治疗未观察到死亡、因不良事件停药或特殊关注不良事件。
- 第57天MG-ADL评分变化呈显著剂量反应(线性趋势检验p=0.031)。
核心结论
- 尼泊卡利单抗在这项2期研究中总体安全、耐受性良好,并显示第57天MG-ADL评分呈剂量依赖性降低的证据。
- 这些结果支持进一步评估尼泊卡利单抗治疗全身型重症肌无力。
研究设计与样本
- 2期研究,68例对稳定标准治疗反应不足的全身型重症肌无力患者按1:1:1:1:1随机分配至静脉安慰剂每2周一次或四种静脉尼泊卡利单抗方案之一,并继续背景标准治疗。
- 四种尼泊卡利单抗方案为5 mg/kg每4周一次、30 mg/kg每4周一次、60 mg/kg每2周一次共8周、60 mg/kg单次给药;所有组均每2周输注以保持盲法。
- 主要安全性终点为治疗中出现的不良事件发生率,包括严重不良事件和特殊关注不良事件;主要疗效终点为MG-ADL总分从基线至第57天的变化。
主要发现
- 68例患者被随机分配(尼泊卡利单抗n=54;安慰剂n=14);64例(94.1%)抗乙酰胆碱受体自身抗体阳性,4例(6%)抗肌肉特异性酪氨酸激酶自身抗体阳性。
- 57例患者(83.8%)完成治疗至第57天。
- 尼泊卡利单抗联合组与安慰剂组治疗中出现的不良事件发生率相似(83.3% vs 78.6%),感染发生率分别为33.3% vs 21.4%。
- 尼泊卡利单抗治疗未观察到死亡或因治疗中出现的不良事件停药,也未观察到特殊关注的不良事件(≥3级感染或低白蛋白血症)。
- 第57天MG-ADL评分从基线的变化呈统计学显著的剂量反应(线性趋势检验p=0.031)。
关键数值与推荐
- 尼泊卡利单抗联合组与安慰剂组治疗中出现的不良事件发生率:83.3% vs 78.6%。
- 尼泊卡利单抗联合组与安慰剂组感染发生率:33.3% vs 21.4%。
- 第57天MG-ADL评分从基线变化的剂量反应线性趋势检验p=0.031。
- 证据等级:本研究提供I级证据,表明对全身型重症肌无力患者,尼泊卡利单抗耐受性良好,任一单剂量未显著改善MG-ADL,但跨剂量显示改善MG-ADL的显著剂量反应。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: To evaluate in a phase 2 study the safety and efficacy of IV nipocalimab, a fully human, antineonatal Fc receptor monoclonal antibody, in patients with generalized myasthenia gravis (gMG). METHODS: Patients with gMG with inadequate response to stable standard-of-care (SOC) therapy were randomized 1:1:1:1:1 to receive either IV placebo every 2 weeks (Q2W) or one of 4 IV nipocalimab treatments: 5 mg/kg once every 4 weeks (Q4W), 30 mg/kg Q4W, 60 mg/kg Q2W each for 8 weeks, or a 60 mg/kg single dose, in addition to their background SOC therapy. Infusions (placebo or nipocalimab) were Q2W in all groups to maintain blinding. The primary safety endpoint was incidence of treatment-emergent adverse events (TEAEs), including serious adverse events and adverse events of special interest. The primary efficacy endpoint was change from baseline to day 57 in Myasthenia Gravis-Activities of Daily Living (MG-ADL) total scores. Dose response of change at day 57 was analyzed with a linear trend test over the placebo, nipocalimab 5 mg/kg Q4W, nipocalimab 30 mg/kg Q4W, and nipocalimab 60 mg/kg Q2W groups. RESULTS: Sixty-eight patients (nipocalimab: n = 54; placebo, n = 14) were randomized; 64 patients (94.1%) were positive for antiacetylcholine receptor autoantibodies, and 4 patients (6%) were positive for antimuscle-specific tyrosine kinase autoantibodies. Fifty-seven patients (83.8%) completed treatment through day 57. The combined nipocalimab group compared with the placebo group demonstrated similar incidences of TEAEs (83.3% vs 78.6%, respectively) and infections (33.3% vs 21.4%, respectively). No deaths or discontinuations due to TEAEs and no TEAEs of special interest (grade ≥3 infection or hypoalbuminemia) were observed with nipocalimab treatment. A statistically significant dose response was observed for change from baseline in MG-ADL at day 57 (p = 0.031, test of linear trend). DISCUSSION: Nipocalimab was generally safe, well-tolerated, and showed evidence of dose-dependent reduction in MG-ADL scores at day 57 in this phase 2 study. These results support further evaluation of nipocalimab for the treatment of gMG. TRIAL REGISTRATION INFORMATION: Clinical Trials Registration: NCT03772587; first submitted December 10, 2018; EudraCT Number: 2018-002247-28; first submitted November 30, 2018; date of first patient dosed April 10, 2019. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that for patients with gMG, nipocalimab was well-tolerated, and it did not significantly improve MG-ADL at any individual dose but demonstrated a significant dose response for improved MG-ADL across doses.
引用
- Antozzi C, Guptill J, Bril V, et al. Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis: Results From the Randomized Phase 2 Vivacity-MG Study. Neurology. 2023. PMID: 38165333. doi:10.1212/WNL.0000000000207937
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。